Phathom Pharmaceuticals (PHAT) Assets Average (2019 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Assets Average of $316.1 million for Q2 2026, up 16.12% year-over-year from $272.2 million in Q2 2025, and up 12.04% quarter-over-quarter from $282.1 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Assets Average (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Assets Average for 8 consecutive years, with $316.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Assets Average rose 16.12% year-over-year to $316.1 million; the TTM figure through Jun 2026 stood at $316.1 million (up 16.12% YoY), while the FY2025 annual figure was $318.7 million, down 19.53% from the prior year.
- Assets Average rose to $316.1 million in Q2 2026 per PHAT's latest filing, from $282.1 million in the prior quarter.
- Across five years, Assets Average topped out at $385.2 million in Q1 2024 and bottomed at $154.4 million in Q1 2023.
- Historically, Assets Average has averaged $268.8 million across 5 years, with a median of $261.6 million in 2023.
- Annual changes were most pronounced in 2022 — Assets Average slumped 37.49% — and 2024, when it soared 149.45%.
- Phathom Pharmaceuticals' Assets Average stood at $183.4 million in 2022, then surged by 77.46% to $325.4 million in 2023, then grew by 17.6% to $382.7 million in 2024, then slumped by 34.74% to $249.7 million in 2025, then rose by 26.58% to $316.1 million in 2026.
- Business Quant data shows PHAT's Assets Average at $316.1 million in Q2 2026, $282.1 million in Q1 2026, and $249.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | 316.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 316.10 Mn |
| Mar 31, 2026 | 282.13 Mn |
| Dec 31, 2025 | 249.72 Mn |
| Sep 30, 2025 | 245.25 Mn |
| Jun 30, 2025 | 272.21 Mn |
| Mar 31, 2025 | 336.26 Mn |
| Dec 31, 2024 | 382.68 Mn |
| Sep 30, 2024 | 353.21 Mn |
| Jun 30, 2024 | 337.94 Mn |
| Mar 31, 2024 | 385.17 Mn |
| Dec 31, 2023 | 325.42 Mn |
| Sep 30, 2023 | 251.02 Mn |
| Jun 30, 2023 | 204.52 Mn |
| Mar 31, 2023 | 154.41 Mn |
| Dec 31, 2022 | 183.37 Mn |
| Sep 30, 2022 | 207.72 Mn |
| Jun 30, 2022 | 181.28 Mn |
| Mar 31, 2022 | 169.24 Mn |
| Dec 31, 2021 | 208.90 Mn |
| Sep 30, 2021 | 221.48 Mn |